PURPOSE: Osteosarcoma is primary malignant tumour of bone. Kruppel-like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in a number of human cancers and a ubiquitously expressed zinc-finger transcription factor. The present study aimed to first explore the relationship between the expression level of the KLF6 gene in osteosarcoma and the occurrence of bone tumours. METHODS: KLF6 mRNA and protein expression levels in osteosarcoma and normal bone tissue were assayed by real-time quantitative PCR and immunohistochemistry. KLF6 mRNA and protein expression levels in osteosarcoma cells and normal osteoblasts were detected by semi-quantitative reverse transcription PCR and Western blotting, respectively. RESULTS: Both the expression of KLF6 mRNA and protein in osteosarcoma cells and tissues were significantly lower than that in normal cells and tumour-adjacent tissues. CONCLUSIONS: KLF6 is a putative tumor suppressor gene involved in osteosarcoma which can be used as a new therapeutic target and an important marker for early diagnosis and postoperative monitoring.
PURPOSE:Osteosarcoma is primary malignant tumour of bone. Kruppel-like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in a number of humancancers and a ubiquitously expressed zinc-finger transcription factor. The present study aimed to first explore the relationship between the expression level of the KLF6 gene in osteosarcoma and the occurrence of bone tumours. METHODS:KLF6 mRNA and protein expression levels in osteosarcoma and normal bone tissue were assayed by real-time quantitative PCR and immunohistochemistry. KLF6 mRNA and protein expression levels in osteosarcoma cells and normal osteoblasts were detected by semi-quantitative reverse transcription PCR and Western blotting, respectively. RESULTS: Both the expression of KLF6 mRNA and protein in osteosarcoma cells and tissues were significantly lower than that in normal cells and tumour-adjacent tissues. CONCLUSIONS:KLF6 is a putative tumor suppressor gene involved in osteosarcoma which can be used as a new therapeutic target and an important marker for early diagnosis and postoperative monitoring.
Authors: G Bacci; A Briccoli; M Rocca; S Ferrari; D Donati; A Longhi; F Bertoni; P Bacchini; S Giacomini; C Forni; M Manfrini; S Galletti Journal: Ann Oncol Date: 2003-07 Impact factor: 32.976
Authors: M Serra; G Reverter-Branchat; D Maurici; S Benini; J-N Shen; T Chano; C-M Hattinger; M-C Manara; M Pasello; K Scotlandi; P Picci Journal: Ann Oncol Date: 2004-01 Impact factor: 32.976
Authors: Moran Rubinstein; Gila Idelman; Stephen R Plymate; Goutham Narla; Scott L Friedman; Haim Werner Journal: Endocrinology Date: 2004-05-06 Impact factor: 4.736
Authors: Helen L Reeves; Goutham Narla; Olagunju Ogunbiyi; Asif I Haq; Amanda Katz; Sharon Benzeno; Eldad Hod; Noam Harpaz; Shlomit Goldberg; Sigal Tal-Kremer; Francis J Eng; Michael J P Arthur; John A Martignetti; Scott L Friedman Journal: Gastroenterology Date: 2004-04 Impact factor: 22.682
Authors: Sharon Benzeno; Goutham Narla; Jorge Allina; George Z Cheng; Helen L Reeves; Michaela S Banck; Joseph A Odin; J Alan Diehl; Doris Germain; Scott L Friedman Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Keishi Yamashita; Sunil Upadhyay; Motonobu Osada; Mohammad O Hoque; Yan Xiao; Masaki Mori; Fumiaki Sato; Stephen J Meltzer; David Sidransky Journal: Cancer Cell Date: 2002-12 Impact factor: 31.743